Artikkelit

A little over a year ago, Sara, 34, received life-changing news: She had been diagnosed with type 1 diabetes. A condition often associated with children and adolescents had suddenly appeared in adulthood. The diagnosis meant adjusting to a new daily routine and undergoing significant mental adaptation. It also brought insights and a deeper understanding of herself. Living in Helsinki, Sara openly shares how her life has changed and how even a little humor can help during challenging times.

When Kris from Oulu heard two years ago that her 16-year-old son Allan had been diagnosed with type 1 diabetes, her world stopped for a moment. Allan, who lives in Rovaniemi with his father, had been symptomatic for a while, but the family hadn't connected the symptoms to a serious illness. The diagnosis was a shock that permanently changed the family's daily life – and Allan's future dream.

The Bright study demonstrated similar efficacy and safety of Toujeo^® (Glargine 300 U/ml) compared to degludec 100 U/ml in type 2 diabetes patients who had not previously received basal insulin¹.

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives⁸.

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Explore the clinical presentation and pathophysiology of Prurigo Nodularis (PN), including its systemic inflammation, itching-scratching cycle, and effects on quality of life. Learn about the underlying mechanisms and treatment options for this chronic skin condition.